You make a compelling point about the potential negative impact on innovation

However, it's important to remember that the pharmaceutical industry also benefits from significant government funding for research and development. For instance, the National Institutes of Health (NIH) invests over $41.7 billion annually in medical research. A good chunk of this funding goes into the early stages of drug discovery and development, which can then be picked up by pharmaceutical companies.

Moreover, many countries with universal healthcare systems, like Canada and the UK, have government involvement in drug price negotiations, and yet their pharmaceutical industries continue to innovate.

Could there be a way to use a tiered or case-by-case approach to drug price negotiations? This could potentially protect the incentives for innovation while still reducing prices for certain high-cost drugs. What do you think?